Emyria Ltd · ASX:EMD
Emyria — Investor Presentation (July 2026)
22 slides from Emyria's investor presentation, Jul 27, 2026
Slide 1: Delivering the new paradigm in mental health care
ASX : EMD For personal use only Delivering the new paradigm in mental health care Techknow Presentation July 2026 1 Advanced therapies. Compassionate care.
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Emyria Limited ACN 625 085 734 (Company or Emyria). This presentation is not a financial product or investment advice or recommendation, offer or invitation by any person or to any person to sell or purchase securities in Emyria in any jurisdiction.
Slide 3: Who are we?
Who are we? Emyria is addressing a significant and escalating gap in the mental healthcare market Emyria is building a national network of clinics For personal use only specialising in delivery of Psychedelic Assisted Therapy for PTSD and Treatment Resistant Depression. 3 Advanced therapies. Compassi
Slide 4: Worldwide first mover advantage
Worldwide first mover advantage A Regulated Access Pathway For Psychedelics to Treat our Most Serious and Urgent Mental Health Conditions For personal use only MDMA-assisted therapy This regulation Australia For PTSD change has is the FIRST jurisdiction in created a the world to reschedule Psilocybin
Slide 5: Patient journey | Treatment model + bed capacity
Patient journey I Treatment model + bed capacity Medication, ~90 hours of Supervised Intensive Psychotherapy, Follow-Up ACTIVE TREATMENT PROTOCOL BED CAPACITY For personal use only Dosing Dosing Clinic Beds days / SCREENING Day 3 week Dosing Dosing AND Day 1 Day 2 (8 hrs) FOLLOW-UP PREPARATION (8 hr
Slide 6: Emyria's PTSD program is delivering durable and lasting results
Emyria’s PTSD program is delivering durable and lasting results Durable symptom and quality of life improvement, beyond 12 months Average PCL-5 1 Scores by Visit (up to 12 months follow-up) For personal use only Typical last treatment Emyria Real-World Data as of Dec 31st 2025 ~67% of patients no lo
Slide 7: Emyria's Treatment Resistant Depression program early outcomes
Emyria’s Treatment Resistant Depression program early outcomes1 First Cohort of 10 patients - Clinically Significant Improvement For personal use only Clinically significant reductions in: - Depression Symptoms - Trauma Symptions Improvements in: - Quality of Life - Daily functioning All changes stati
Slide 8: Major Funders are spending Hundreds of Millions each year on mental health
Major Funders are spending Hundreds of Millions each year on mental health For personal use only Private Department of Other Health Insurers Veterans’ Affairs Insurers The Government spends Life insurers … paid out more than $2B $300M/yr on veteran mental health each year. 2 $2.2B in 2024 spent by M
Slide 9: MDMA-AT cost vs standard of care for PTSD
MDMA-AT cost 1 vs standard of care for PTSD 2, 3 Ongoing care Emyria’s intensive, 6-12 week ~ $33,000 / yr 1 program 1 Neurostimulation (~$3,000) For personal use only 60 Typical standard of care ~ $60,000 / yr 2 interventions 2 50 Cumulative costs ($1,000s of AUD) 2-week hospital admission 2 (~$24,
Slide 10: Third party funding
Third party funding Reimbursement has commenced for Psychedelic Assisted Therapy For personal use only Other ad Key funding bodies1,2 Work in progress hoc approvals Case by case We continue to approvals have engage other private occurred from other health insurers, funding bodies workers compensatio
Slide 11: Typical timeline to projected clinic profitability
Typical timeline to projected clinic profitability Current Clinic Status Investment Phase Revenue Generation For personal use only Fit-out & recruitment commences Projected break-even point Months 1-3 Months 4-6 Months 6-9 Months 9-12+ Clinic set-up Open clinic & Dosing day ramp-up Optimise dosing co
Slide 12: Maturing clinic | Perth Clinic dosing days May 2025 to June 2026
Maturing clinic I Perth Clinic dosing days May 2025 to June 2026 31 For personal use only Seasonal Impact –Easter Seasonal Impact - Christmas SOURCES: 1. See ASX announcement 11 June 2026 * Monthly stand alone clinic breakeven. 12 Advanced therapies. Compassionate care.
Slide 13: Highly defensible healthcare business
Highly defensible healthcare business For personal use only Skilled Secure Therapists Drug Supply Third Authorised Party Prescribers Funding Proven Fit-for- Purpose Clinical Model Facilities 13 Advanced therapies. Compassionate care.
Slide 14: Scalable contractor workforce
Scalable contractor workforce Capital light and flexible workforce to support growing clinic utilisation For personal use only Therapists trained and Authorised Prescribers contracted (AP) 8 approved Perth (x2 Clinic) ~35 1 in application process Brisbane ~25 5 approved 1 approved Melbourne ~25 3 in
Slide 15: Significant momentum in psychedelic drug treatments
Significant momentum in psychedelic drug treatments Recent macro catalysts provide significant tailwinds for Emyria For personal use only Emyria is well positioned to leverage this momentum, writing the playbook for psychedelic drug delivery SOURCES 1. https://psychedelics.berkeley.edu/clinical-trials
Slide 16: Potential future treatable conditions
Potential future treatable conditions Significant global research in psychedelic drugs For personal use only New Treatable Conditions Increase Total Addressable Market SOURCES 1. https://psychedelics.berkeley.edu/clinical-trials-map 16 Advanced therapies. Compassionate care.
Slide 17: Emyria has established versatile delivery infrastructure
Emyria has established versatile delivery infrastructure Infrastructure able to support growing, global research effort into psychedelic drugs For personal use only More treatment types Third party clinical trials Can support future potential indications Can support clinical trials delivery and trea
Slide 18: Corporate Overview
Corporate Overview Share Price, trading history ASX: EMD Trading Information For personal use only Last Traded Share Price A$0.044 12-Month low / high A$0.021 / 0.078 Shares Outstanding 806,483,233 Unlisted Options (including loyalty options) 310,147,902 Market Capitalisation 1 ~A$35m Last Cash Posi
Slide 19: Emyria | Summary
Emyria | Summary For personal use only Significant Total Generating revenue First mover advantage Addressable Market globally Qtr on Qtr Growth AUS + globally Capital Light approach Delivering durable Developing the P-AT to clinics expansion outcomes playbook 19 Advanced therapies. Compassionate care
Slide 20: Emyria | Executing strongly
Emyria (ASX:EMD) | Executing strongly Delivering on commitments to shareholders For personal use only Recent Achievements Future Drivers: • 1st Private Health Insurer Funding • 1st DVA approval treatments (Medibank) • Open Sydney Clinic • Opened 2nd Perth Empax Clinic • Additional New Sites Confirmed
Slide 21: Emyria Board
Emyria Board Significant Clinical Services & Global Innovation Expertise For personal use only Greg Hutchinson Dr Michael Winlo Dr Karen Smith Dr Mohit Kaushal Prof Sir John Tooke Executive Chairman Executive Director Non-Executive Director Non-Executive Director Non-Executive Director Health Service
Slide 22: Contact Information
Contact Information For personal use only Greg Hutchinson ghutchinson@emyria.com Mary-Ann Rennie mrennie@emyria.com Visit Our Investor / Investor Hub Media Inquiries investors@emyria.com